BackAridis Pharmaceuticals Overview

Aridis Pharmaceuticals Net Income

Aridis Pharmaceuticals's net income is $-640K, below the Healthcare sector average of $16B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$83000.00
99.08% YoY

As of Sep 2023

Annual Net Income (TTM)

-$635000.00
98.22% YoY

Trailing 12 months ending Sep 2023

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Aridis Pharmaceuticals (ARDS) FAQ

Aridis Pharmaceuticals (ARDS) currently reports a net income of $-640K as of September 2023. That compares with $-36M in the prior-year period — up 98.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Aridis Pharmaceuticals's net income history and peer comparisons.

Aridis Pharmaceuticals's net income increased from $-36M to $-640K — a 98.2% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aridis Pharmaceuticals's net income of $-640K is lower than the Healthcare sector average of $16B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Aridis Pharmaceuticals reported $-640K in net income as of September 2023. That compares with $-36M in the prior-year period — up 98.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-640K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Aridis Pharmaceuticals, and consider following ARDS for alerts when major investors trade the stock.